Author Affiliation: Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
In the past decade, tuberculosis (TB) has recaptured the interest of
the medical community and the public because of its impolite refusal to go
away when asked. The numbers are now familiar: 2 billion people worldwide
with latent infection, 8 million new cases a year, and up to 2 million annual
deaths.1 Equally alarming is the emergence
of drug resistance to TB on all continents and the explosive interaction between Mycobacterium tuberculosis and the human immunodeficiency
Sepkowitz KA. Further Adventures of the Tubercle Bacillus. JAMA. 2000;284(13):1701-1702. doi:10.1001/jama.284.13.1701